Literature DB >> 1535036

Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo.

O Bagasra1, A Howeedy, R J Pomerantz.   

Abstract

In order to obtain a better understanding of the degree of immune dysfunctions caused by the absence of adenosine deaminase, we gave a single i.p. injection of 2'-deoxycoformycin (2-dcf), a potent inhibitor of the enzyme ADA at various doses into adult Syrian hamsters. These animals were examined for their ability to mount primary in vivo antibody responses to helper T cell dependent (Th-d) and helper T cell independent (Th-ind) antigens. Hamsters treated with 0.5 mg/kg of 2-dcf mounted enhanced splenic plaque-forming cell (PFC) responses to sheep erythrocytes, a Th-d antigen, and to pneumococcal polysaccharide type III (SIII), a Th-ind antigen. Treatment of animals with 1.0 mg/kg of 2-dcf resulted in a significantly depressed (P less than 0.001) PFC response to Th-d antigen, but a further enhanced response to Th-ind antigen. One mechanism which may be responsible for such a dichotomous response to these two types of antigens was selective dysfunction of T cell subpopulations. At higher doses (1.5-4.0 mg/kg), PFC responses to both types of antigens were significantly suppressed. Immunoenhancement at low doses of 2-def was attributed to an increased susceptibility of T suppressor cells to 2-dcf. This hypothesis was confirmed by priming the 2-dcf-treated animals with low-dose Th-ind antigens. These animals failed to induce low-dose tolerance by stimulation of antigen-specific suppressor T cell subsets. At low doses, B cells and T helper cell functions were found to be intact, as further confirmed by priming the animals with the carrier keyhole limpet haemocyanin (KLH) and challenging with trinitrophenyl-KLH. This dose-dependent selective susceptibility of various T cell subpopulations and B cells may explain the heterogeneity of clinical, biochemical and immunological parameters observed in children with ADA deficiency severe combined immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1535036      PMCID: PMC1554516          DOI: 10.1111/j.1365-2249.1992.tb06458.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Regulation of the antibody response to type III pneumococcal polysaccharide. V. Ontogeny of factors influencing the magnitude of the plaque-forming cell response.

Authors:  H C Morse; B Prescott; S S Cross; P W Stashak; P J Baker
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

2.  Enhancement of the antibody response to type 3 pneumococcal polysaccharide in mice treated with antilymphocyte serum.

Authors:  P J Baker; R F Barth; P W Stashak; D F Amsbaugh
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

3.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

4.  Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells.

Authors:  R S Kerbel; D Eidinger
Journal:  Eur J Immunol       Date:  1972-04       Impact factor: 5.532

5.  An improved assay for haemolytic plaque-forming cells.

Authors:  J C Kennedy; M A Axelrad
Journal:  Immunology       Date:  1971-02       Impact factor: 7.397

6.  Antitrinitrophenyl (TNP) plaque assay. Primary response of Balb/c mice to soluble and particulate immunogen.

Authors:  M B Rittenberg; K L Pratt
Journal:  Proc Soc Exp Biol Med       Date:  1969-11

7.  Effects of deoxycoformycin in mice. I. Suppression and enhancement of in vivo antibody responses to thymus-dependent and -independent antigens.

Authors:  H Ratech; M K Bell; R Hirschhorn; G J Thorbecke
Journal:  J Immunol       Date:  1984-06       Impact factor: 5.422

8.  Immunosuppressive effects of pentostatin.

Authors:  E H Kraut; J C Neff; B A Bouroncle; D Gochnour; M R Grever
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

9.  Functional analysis of T-cell subsets in chronic experimental alcoholism.

Authors:  O Bagasra; A Howeedy; R Dorio; A Kajdacsy-Balla
Journal:  Immunology       Date:  1987-05       Impact factor: 7.397

10.  Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse.

Authors:  J K Nicholson; D S Gordon; J S McDougal
Journal:  Cell Immunol       Date:  1983-07-15       Impact factor: 4.868

View more
  2 in total

1.  Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease.

Authors:  Ming J Poi; Craig C Hofmeister; Jeffrey S Johnston; Ryan B Edwards; Buffy S Jansak; David M Lucas; Sherif S Farag; James T Dalton; Steven M Devine; Michael R Grever; Mitch A Phelps
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

2.  Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms.

Authors:  Barbara Kutryb-Zajac; Patrycja Koszalka; Paulina Mierzejewska; Alicja Bulinska; Magdalena A Zabielska; Karolina Brodzik; Aleksandra Skrzypkowska; Lukasz Zelazek; Iwona Pelikant-Malecka; Ewa M Slominska; Ryszard T Smolenski
Journal:  J Cell Mol Med       Date:  2018-10-05       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.